Fujifilm profit falls 30% as plant launch costs weigh on healthcare unit

Shares fell as much as 18% after first-quarter earnings missed analyst estimates, while Fujifilm reviewed a partial spin-off of its Business Innovation unit.

Summary

Fujifilm Holdings said April-June fiscal 2026 net profit fell 30% year-on-year to ¥37.4 billion as launch costs at new biopharmaceutical CDMO plants, higher raw material and component costs, and ERP overhaul expenses weighed on earnings. Revenue rose 10% to ¥826.4 billion, but operating profit of about ¥51.1 billion to ¥51.2 billion missed Bloomberg's ¥77.1 billion analyst estimate, and the stock fell as much as 18%, its steepest drop on record. The company raised its full-year revenue forecast to ¥3.56 trillion on stronger semiconductor materials sales but kept net profit guidance at ¥280 billion, and said it is studying a partial spin-off and Tokyo Stock Exchange listing of Fujifilm Business Innovation within two to three years, with Fujifilm retaining less than 20% if the plan proceeds.

Terms & Concepts
  • CDMO: Contract development and manufacturing organization, a company that develops and manufactures pharmaceuticals or biologics for clients.
  • ERP: Enterprise resource planning, a company-wide software system used to manage core business processes.
  • Dividend-in-kind: A non-cash distribution to shareholders, such as shares in a spun-off company.